Pfizer Inc
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Zavicefta (ceftazidime/avibactam by Year
Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide revenues ($M) ($M)
Pfizer Zavicefta (ceftazidime/avibactam: $638M in FY2025, up 8.9% from a year earlier. That is the highest of the 8 years on record here.
Where the FY2025 figure comes from
“|| Zavicefta (Outside the U.S. and Canada) | 638 | 586 | 9% | 9% | — | — | — | 638 | 586 | 9% | 9%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 638 | +8.9% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 586 | +14.7% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 511 | +396.1% | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 103 | -18.3% | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2021 | Dec 31, 2021 | 126 | +63.6% | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2020 | Dec 31, 2020 | 77 | +28.3% | Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗ |
| FY2019 | Dec 31, 2019 | 60 | +30.4% | Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗ |
| FY2018 | Dec 31, 2018 | 46 | – | Form 10-K (filed 2021-02-25) ↗ |
Breakdown
What makes up zavicefta (ceftazidime/avibactam
- Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — International revenues ($M)638 · FY2025
- Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide reported YoY (%)9.0% · FY2025
- Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide operational (constant-currency) YoY (%)9.0% · FY2025
Cite this data
StockData. (2026). Pfizer Zavicefta (ceftazidime/avibactam ($M), annual FY2018–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/zavicefta-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?